查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612838

感染疾病的体外诊断的全球市场:产业分析，规模，占有率，成长，趋势，预测(2024年～2031年)

Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 188 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计2024年全球传染病体外诊断市场规模将达445亿美元，2024年至2031年预测期间复合年增长率为4.7%，2031年将达612亿美元。

传染病体外诊断市场是指用于检测细菌、病毒、真菌、寄生虫等病原体引起的传染病的诊断测试。这些诊断测试对于传染病的早期发现、管理和治疗至关重要。该市场的推动因素包括全球传染病患者病率上升、诊断技术的技术进步以及对快速准确诊断工具的需求不断增长，特别是在全球大流行之后。该市场包括分子诊断、免疫分析和微生物检测等各领域。

有几个因素促进了全球传染病体外诊断市场的发展，包括传染病发病率的上升（尤其是在发展中地区）以及医疗基础设施的成长。人们对早期诊断的认识不断提高，以及对传染病即时检测（POC​​T）的需求不断增长，进一步推动了市场的成长。 COVID-19、结核病、爱滋病毒和疟疾等疾病的发生率不断增加，也增加了对准确、快速诊断工具的需求。此外，分子诊断和下一代定序（NGS）的技术进步预计将推动市场向前发展。

传染病体外诊断市场提供了巨大的商机，特别是在新兴国家，传染病负担的日益增加正在推动对更好诊断工具的需求。分子诊断的进步，包括基于 PCR 的技术和 CRISPR，为创新和扩展提供了新的机会。此外，个人化医疗的不断增长趋势和多重测试平台的发展为市场进入者提供了成长途径。此外，诊断公司和医疗保健提供者之间日益加强的合作预计将为市场扩张带来新的机会。

本报告提供全球感染疾病的体外诊断市场相关调查，提供各产品类型，各技术，各用途，各终端用户，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 摘要整理

第2章 市场概要

  • 市场范围和定义
  • 市场动态
  • 宏观经济要素
  • COVID-19影响分析
  • 预测要素- 相关性及影响

第3章 附加价值的洞察

第4章 全球感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

  • 主要的焦点
  • 市场规模(10亿美元)分析与预测
  • 全球感染疾病的体外诊断市场预测:各产品类型
  • 市场魅力分析:各产品类型
  • 全球感染疾病的体外诊断市场预测:各技术
  • 市场魅力分析:各技术
  • 全球感染疾病的体外诊断市场预测:各用途
  • 市场魅力分析:各用途
  • 全球感染疾病的体外诊断市场预测:各终端用户
  • 市场魅力分析:各终端用户

第5章 全球感染疾病的体外诊断市场预测:各地区

  • 主要的焦点
  • 过去的市场规模(10亿美元)分析，各地区，2019年～2023年
  • 目前市场规模(10亿美元)的分析与预测，各地区，2024年～2031年
  • 市场魅力分析:各地区

第6章 北美的感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

第7章 欧洲的感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

第8章 东亚的感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

第9章 南亚及大洋洲的感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

第10章 南美的感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

第11章 中东·非洲的感染疾病的体外诊断市场预测:实际成果(2019年～2023年)及预测(2024年～2031年)

第12章 竞争情形

  • 市场占有率分析，2023年
  • 市场结构
  • 企业简介(详细内容- 概要，财务，策略，最近的趋势)
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc. (Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.

第13章 附录

简介目录
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Infectious Disease In-vitro Diagnostics Market Size (2024E): US$ 44.5 Bn
  • Projected Market Value (2031F): US$ 61.2 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

The Infectious Disease In-vitro Diagnostics market refers to diagnostic tests used for detecting infections caused by pathogens such as bacteria, viruses, fungi, and parasites. These diagnostic tests are essential in the early detection, management, and treatment of infectious diseases. The market is driven by rising global infectious disease prevalence, technological advancements in diagnostic technologies, and an increasing need for rapid and accurate diagnostic tools, especially in the wake of global pandemics. The market encompasses various segments, including molecular diagnostics, immunoassays, and microbiology testing.

Market Growth Drivers:

Several factors are contributing to the growth of the global Infectious Disease IVD market, including the rising incidence of infectious diseases, especially in developing regions, and growing healthcare infrastructure. Increasing awareness about early diagnosis and the growing demand for point-of-care testing (POCT) for infectious diseases are further propelling market growth. The need for accurate and rapid diagnostic tools is also rising due to the increasing frequency of outbreaks of diseases such as COVID-19, tuberculosis, HIV, and malaria. Additionally, technological advancements in molecular diagnostics and next-generation sequencing (NGS) are expected to drive the market forward.

Market Restraints:

Despite its growth potential, the Infectious Disease IVD market faces challenges such as high costs associated with advanced diagnostic tests, particularly in low-income regions. Regulatory hurdles in some countries, along with the need for extensive validation and certification of diagnostic products, may also limit market expansion. Moreover, the lack of awareness in remote areas regarding the availability and benefits of in-vitro diagnostics poses a barrier to the widespread adoption of diagnostic tools.

Market Opportunities:

The Infectious Disease IVD market presents significant opportunities, particularly in emerging economies, where the demand for better diagnostic tools is growing due to the rising burden of infectious diseases. Advancements in molecular diagnostics, including PCR-based technologies and CRISPR, offer new opportunities for innovation and expansion. Further, the increasing trend toward personalized medicine and the development of multiplex testing platforms provide growth avenues for market players. Additionally, the rise in collaborations between diagnostic companies and healthcare providers is expected to open new opportunities for market expansion.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global Infectious Disease IVD market?
  • Which diagnostic technologies and testing platforms are leading the market in terms of demand and revenue?
  • How are advancements in molecular diagnostics and PCR technologies influencing the Infectious Disease IVD market?
  • Who are the leading players in the Infectious Disease IVD market, and what strategies are they employing to maintain their market positions?
  • What are the emerging trends and future prospects in the global Infectious Disease IVD market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Infectious Disease IVD market, such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, are focusing on enhancing their product portfolios, including rapid diagnostics and molecular testing platforms. These companies are investing in innovative technologies such as real-time PCR, next-generation sequencing (NGS), and point-of-care testing solutions. Collaborations with healthcare providers, research institutions, and public health organizations are critical to expanding market reach. Moreover, focusing on regulatory compliance, product differentiation, and technological advancements will help companies maintain a competitive edge and capitalize on the growing demand for efficient and accurate infectious disease diagnostics.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease In-vitro Diagnostics Industry Segmentation

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19

By End User

  • Point-of-care
  • Central Laboratories

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-Vitro Diagnostics Market Snapshot, 2024 - 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. Parent Market Analysis
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
  • 4.3. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
  • 4.4. Market Attractiveness Analysis: Product Type
  • 4.5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Technology
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019 - 2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
      • 4.5.3.1. Immunoassay
      • 4.5.3.2. Molecular Diagnostics
      • 4.5.3.3. Microbiology
      • 4.5.3.4. Others
  • 4.6. Market Attractiveness Analysis: Technology
  • 4.7. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Application
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
      • 4.7.3.1. MRSA
      • 4.7.3.2. Clostridium Difficile
      • 4.7.3.3. Respiratory Virus
      • 4.7.3.4. TB and Drug-resistant TB
      • 4.7.3.5. Gonorrhea
      • 4.7.3.6. HPV
      • 4.7.3.7. HIV
      • 4.7.3.8. Hepatitis C
      • 4.7.3.9. Hepatitis B
      • 4.7.3.10. COVID-19
      • 4.7.3.11. Others
  • 4.8. Market Attractiveness Analysis: Application
  • 4.9. Global Infectious Disease In-Vitro Diagnostics Market Outlook: End User
    • 4.9.1. Introduction / Key Findings
    • 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
    • 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
      • 4.9.3.1. Point-of-care
      • 4.9.3.2. Central Laboratories
      • 4.9.3.3. Others
  • 4.10. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations